Is Icon a buyout target?; Covance pads its executive suite;

> With its double-digit annual growth and tax-friendly Irish domicile, Icon ($ICLR) could be an M&A target. Item

> Covance ($CVD) added two vice presidents, appointing Roche ($RHHBY) veteran Robert Wasserman as head of oncology and former AstraZeneca ($AZN) exec Rogelio Mosqueda-Garcia to lead the early clinical services segment of its medical and scientific affairs business. More

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.